Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on CaV2.1 channels via PIP2 depletion

Journal of Neurophysiology

Volumn 105, Issue 5, 2011, Pages 2260-2274

  Aleph Prieto, G ^a   Perez Burgos, Azucena ^a   Rivero, Marcela Palomero ^a   Galarraga, Elvira ^a   Drucker Colin, Rene ^a   Bargas, Jose ^a  

^a INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

Author keywords

6 hydroxydopamine; Medium spiny neurons; Parkinson's disease; Supersensitivity

Indexed keywords

CALCIUM CHANNEL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; CALCIUM CHANNEL N TYPE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; VOLTAGE DEPENDENT CALCIUM CHANNEL (P Q TYPE); VOLTAGE-DEPENDENT CALCIUM CHANNEL (P-Q TYPE);

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CALCIUM CURRENT; CELL ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RODENT; SUBSTATIA NIGRA COMPACTA; VOLTAGE CLAMP; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SYMPATHECTOMY; TRANSGENIC MOUSE; UPREGULATION; WISTAR RAT;

ANIMALS; CALCIUM CHANNELS, N-TYPE; CORPUS STRIATUM; DOPAMINE; MALE; MICE; MICE, TRANSGENIC; PHOSPHOINOSITIDE PHOSPHOLIPASE C; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SIGNAL TRANSDUCTION; SYMPATHECTOMY; UP-REGULATION;

EID: 79956268193     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00516.2010     Document Type: Article

References (89)

1. Aceves JJ, Rueda-Orozco PE, Hernández R, Plata V, Ibañez-Sandoval O, Galarraga E, Bargas J. Dopaminergic presynaptic modulation of nigral afferents: its role in the generation of recurrent bursting in substantia nigra pars reticulata neurons. Front Syst Neurosci 5: 6, 2011.
2. Ahlgren-Beckendorf JA, Levant B. Signaling mechanisms of the D3 dopamine receptor. J Recept Signal Transduct Res 24: 117-130, 2004.
3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375, 1989.
4. Azdad K, Chavez M, Don Bischop P, Wetzelaer P, Marescau B, De Deyn PP, Gall D, Schiffmann SN. Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS One 4: e6908, 2009.
5. Bae YS, Lee TG, Park JC, Hur JH, Kim Y, Heo K, Kwak JY, Suh PG, Ryu SH. Identification of a compound that directly stimulates phospholipase C activity. Mol Pharmacol 63: 1043-1050, 2003.
6. 2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci 14: 6667-6686, 1994.
7. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, Kharazia V, Waldhoer M, Mailliard WS, Armstrong R, Bonci A, Whistler JL. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 102: 11521-11526, 2005.
8. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, Borrelli E, Caron MG. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27: 881-885, 2007.
9. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9: 762-767, 2003.
10. Cai G, Wang HY, Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J Pharmacol Exp Ther 302: 1105-1112, 2002.
11. 2 dopamine receptor stimulation in unilateral 6-hydroxydopaminelesioned rats. J Neurosci 20: 1849-1857, 2000.
12. Cangiano A. Denervation supersensitivity as a model for the neural control of muscle. Neuroscience 14: 963-971, 1985.
13. Carrillo-Reid L, Tecuapetla F, Tapia D, Hernandez-Cruz A, Galarraga E, Drucker-Colin R, Bargas J. Encoding network states by striatal cell assemblies. J Neurophysiol 99: 1435-1450, 2008.
14. 3 dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J Neurochem 110: 1180-1190, 2009.
15. Coldwell MC, Boyfield I, Brown AM, Stemp G, Middlemiss DN. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127: 1135-1144, 1999.
16. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197: 596-598, 1977.
17. Dehorter N, Guigoni C, Lopez C, Hirsch J, Eusebio A, Ben-Ari Y, Hammond C. Dopamine-deprived striatal GABAergic interneurons burst and generate repetitive gigantic IPSCs in medium spiny neurons. J Neurosci 29: 7776-7787, 2009.
18. Elmhurst JL, Xie Z, O'Dowd BF, George SR. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Brain Res Mol Brain Res 80: 63-74, 2000.
19. Everett PB, Senogles SE. D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway. Neurosci Lett 371: 34-39, 2004.
20. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97: 99-112, 2000.
21. Fujieda H, Scher J, Lukita-Atmadja W, Brown GM. Gene regulation of melatonin and dopamine receptors during eye development. Neuroscience 120: 301-307, 2003.
22. 3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain. J Pharmacol Exp Ther 274: 1558-1565, 1995.
23. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432, 1990.
24. Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042-5054, 2002.
25. Griffon N, Pilon C, Sautel F, Schwartz JC, Sokoloff P. Two intracellular signaling pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP. J Neurochem 68: 1-9, 1997.
26. Gurevich EV, Himes JW, Joyce JN. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja. J Pharmacol Exp Ther 289: 587-598, 1999.
27. Guzmán JN, Hernández A, Galarraga E, Tapia D, Laville A, Vergara R, Aceves J, Bargas J. Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum. J Neurosci 23: 8931-8940, 2003.
28. 3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp Ther 296: 1074-1084, 2001.
29. Heintz N. Gene expression nervous system atlas (GENSAT). Nat Neurosci 7: 483, 2004.
30. 2+ currents and excitability via a novel PLC-[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20: 8987-8995, 2000.
31. Hopf FW, Cascini MG, Gordon AS, Diamond I, Bonci A. Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunits. J Neurosci 23: 5079-5087, 2003.
32. Hornykiewicz O. The mechanisms of action of L-DOPA in Parkinson's disease. Life Sci 15: 1249-1259, 1974.
33. Hurley MJ, Stubbs CM, Jenner P, Marsden CD. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 214: 75-78, 1996.
34. Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T, Okano H, Nariai T, Ohno K, Obayashi S, Higuchi M, Suhara T. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 1064: 136-145, 2005.
35. Ishibashi T, Wakabayashi J, Ohno Y. 7-Hydroxy-N, N'-di-n-propyl-2-aminotetraline, a preferential dopamine D3 agonist, induces c-fos mRNA expression in the rat cerebellum. Jpn J Pharmacol 89: 309-315, 2002.
36. Jáidar O, Carrillo-Reid L, Hernández A, Drucker-Colín R, Bargas J, Hernández-Cruz A. Dynamics of the Parkinsonian striatal microcircuit: entrainment into a dominant network state. J Neurosci 30: 11326-11336, 2010.
37. Karpa KD, Lin R, Kabbani N, Levenson R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant D3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol Pharmacol 58: 677-683, 2000.
38. Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, Emms F, Freedman SB, Marwood R, Patel S, Ragan CI, Leeson PD. 3-(4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem 39: 1941-1942, 1996.
39. Kuzhikandathil EV, Oxford GS. Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells. J Neurosci 19: 1698-1707, 1999.
40. Lee HJ, Bazinet RP, Rapoport SI, Bhattacharjee AK. Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. Neurochem Res 35: 613-619, 2010.
41. 3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Brain Res 698: 146-154, 1995.
42. Liu K, Bergson C, Levenson R, Schmauss C. On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain. J Biol Chem 269: 29220-29226, 1994.
43. McLaughlin S, Murray D. Plasma membrane phosphoinositide organization by protein electrostatics. Nature 438: 605-611, 2005.
44. Mercuri NB, Saiardi A, Bonci A, Picetti R, Calabresi P, Bernardi G, Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79: 323-327, 1997.
45. Mizuno T, Schmauss C, Rayport S. Distinct roles of presynaptic dopamine receptors in the differential modulation of the intrinsic synapses of mediumspiny neurons in the nucleus accumbens. BMC Neurosci 8: 8, 2007.
46. Nakanishi S, Catt KJ, Balla T. A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids. Proc Natl Acad Sci USA 92: 5317-5321, 1995.
47. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205, 2004.
48. 35S]Guanosine-5′-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282: 181-191, 1997.
49. Newman-Tancredi A, Cussac D, Brocco M, Rivet JM, Chaput C, Touzard M, Pasteau V, Millan MJ. Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. Brain Res 920: 41-54, 2001.
50. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17: 8147-8155, 1997.
51. 2+ channel activity and nuclear signaling. Neuron 55: 261-275, 2007.
52. 2+ channels is dependent on a Shank-binding domain. J Neurosci 25: 1050-1062, 2005.
53. 125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol 50: 1658-1664, 1996.
54. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Elsevier Academic, 2004.
55. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic, 1996.
56. 3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event. Am J Physiol Renal Physiol 287: F1059-F1066, 2004.
57. 1 modulation of N and L types of calcium channels is mediated by protein kinase C in neostriatal neurons. Neuroscience 155: 1079-1097, 2008.
58. V2.1 channels are modulated by muscarinic M1 receptors through phosphoinositide hydrolysis in neostriatal neurons. Neuroscience 165: 293-299, 2010.
59. 2+ channels. J Neurophysiol 93: 2507-2519, 2005.
60. 2+ current modulation in neostriatal neurons. Neuroscience 164: 345-350, 2009.
61. Qin ZH, Chen JF, Weiss B. Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors. J Neurochem 62: 411-420, 1994.
62. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98: 263-273, 2000.
63. Richtand NM, Liu Y, Ahlbrand R, Sullivan JR, Newman AH, McNamara RK. Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression. Synapse 64: 634-643, 2010.
64. Ridray S, Griffon N, Mignon V, Souil E, Carboni S, Diaz J, Schwartz JC, Sokoloff P. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur J Neurosci 10: 1676-1686, 1998.
65. 2+ channels. J Biol Chem 279: 14619-14630, 2004.
66. 2+ channel current and its dopaminergic D2 modulation in developing neostriatal neurons. J Neurophysiol 94: 3771-3787, 2005.
67. 2. J Neurochem 116: 76-81, 2011.
68. Sato K, Ueda H, Okumura F, Misu Y. 6-OHDA-induced lesion of the nigrostriatal dopaminergic neurons potentiates the inhibitory effect of 7-OHDPAT, a selective D3 agonist, on acetylcholine release during striatal microdialysis in conscious rats. Brain Res 655: 233-236, 1994.
69. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 379: 73-86, 2009.
70. Schmauss C. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J Neurosci 16: 7902-7909, 1996.
71. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331, 1996.
72. Seabrook GR, Kemp JA, Freedman SB, Patel S, Sinclair HA, McAllister G. Functional expression of human D3 dopamine receptors in differentiated neuroblastoma × glioma NG108-15 cells. Br J Pharmacol 111: 391-393, 1994.
73. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11: 151-167, 2007.
74. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151, 1990.
75. 125I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295: 1223-1231, 2000.
76. Stefani A, Spadoni F, Martorana A, Lavaroni F, Martella G, Sancesario G, Bernardi G. D2-mediated modulation of N-type calcium currents in rat globus pallidus neurons following dopamine denervation. Eur J Neurosci 15: 815-825, 2002.
77. Suh BC, Hille B. PIP2 is a necessary cofactor for ion channel function: how and why? Annu Rev Biophys 37: 175-195, 2008.
78. Suh BC, Hille B. Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4,5-bisphosphate synthesis. Neuron 35: 507-520, 2002.
79. 2+ channels by membrane phosphatidylinositol 4,5-bisphosphate. Neuron 67: 224-238, 2010.
80. Surmeier DJ, Song WJ, Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16: 6579-6591, 1996.
81. Taverna S, Ilijic E, Surmeier DJ. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci 28: 5504-5512, 2008.
82. Tecuapetla F, Carrillo-Reid L, Bargas J, Galarraga E. Dopaminergic modulation of short-term synaptic plasticity at striatal inhibitory synapses. Proc Natl Acad Sci USA 104: 10258-10263, 2007.
83. Tedford HW, Zamponi GW. Direct G protein modulation of Cav2 calcium channels. Pharmacol Rev 58: 837-862, 2006.
84. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493, 1970.
85. Van Kampen JM, Eckman CB. Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26: 7272-7280, 2006.
86. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94: 11-19, 1993.
87. Wu L, Bauer CS, Zhen XG, Xie C, Yang J. Dual regulation of voltage-gated calcium channels by PtdIns(4,5)P2. Nature 419: 947-952, 2002.
88. Wyllie DJ, Chen PE. Taking the time to study competitive antagonism. Br J Pharmacol 150: 541-551, 2007.
89. Xu C, Watras J, Loew LM. Kinetic analysis of receptor-activated phosphoinositide turnover. J Cell Biol 161: 779-791, 2003.